Gt biopharma to participate in the h.c. wainwright immune cell engager conference on august 17, 2023

Brisbane, california, aug. 03, 2023 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager, trike® platform, today announced that dr. jeffrey miller, md, gt biopharma's consulting chief medical officer and consulting chief scientific officer, will participate in a fireside chat and the keynote session: kol roundtable discussion at h.c. wainwright's immune cell engager conference taking place august 17, 2023. company management will also be participating in 1x1 meetings during the event.
GTBP Ratings Summary
GTBP Quant Ranking